Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors - Scorecard - MDSpire

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors

  • By

  • Darren Hargrave

  • Lynley V. Marshall

  • Nicolas André

  • Julie Krystal

  • Brian H. Ladle

  • Karen A. Robbins

  • Stephan Hois

  • Jon Armstrong

  • Sarah Donegan

  • June 9, 2026

  • 0 min

Share

Clinical Scorecard: Erratum: Phase I/II Multicenter Study Evaluating Durvalumab and Tremelimumab in Pediatric Patients with Advanced Solid Tumors

At a Glance

CategoryDetail
Condition
Key MechanismsCombination of durvalumab and tremelimumab (source needed)
Target Population
Care SettingMulticenter study (source needed)

Key Highlights

  • Correction of misaligned numerical values in Table 1 (source needed)
  • Footnote for histology missing term corrected (source needed)

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Clarify with direct source attribution

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors

            • by Darren Hargrave, Lynley V. Marshall, Nicolas André, Julie Krystal, Brian H. Ladle, Karen A. Robbins, Stephan Hois, Jon Armstrong, Sarah Donegan

            • June 9, 2026

            Related Content

            TIFA: a signaling hub linking inflammation, innate immunity, and human disease

            Editorial: Metabolic cell death in cancer: innovative therapeutic avenues for cancer treatment

            Challenges and emerging strategies for genome-wide evaluation of loss of imprinting in cancer